技术文章您现在的位置:首页 > 技术文章 > BioXcell:InVivoMAb anti-mouse CD172a (SIRPα)单克隆抗体

BioXcell:InVivoMAb anti-mouse CD172a (SIRPα)单克隆抗体

更新时间:2025-03-18   点击次数:128次

P84单克隆抗体,也被称为CD172a抗体,可与信号调节蛋白α(SIRPα)反应。SIRPα蛋白是I型跨膜糖蛋白,在单核细胞、巨噬细胞和树突状细胞均有表达。此外,在神经元和中枢神经系统的一些其他组织也发现有SIRPα蛋白的表达。其配体CD47在多种细胞均有表达。

 

SIRPα和CD47参与调节由树突状细胞介导的T细胞的活化、中性粒细胞迁移和吞噬等过程。SIRPα蛋白可在巨噬细胞的细胞膜上进行横向扩散并在吞噬性突触中积累,与CD47结合后,抑制巨噬细胞的吞噬作用。

 

研究结果表明,使用anti-SIRPα抗体阻断SIRPα与CD47相互作用,可抑制小鼠体内肿瘤的形成。此外,P84(CD172a)单克隆抗体在体内和体外均具有中和活性。

 

BioXcell最新推出InVivoMAb anti-mouse CD172a (SIRPα)单克隆抗体,助力肿瘤免疫检查点研究。如需购买BioXcell公司产品,请联系代理商欣博盛生物。

BE0322.jpg


产品信息:

产品货号

BE0322

产品名称

InVivoMAb   anti-mouse CD172a (SIRPα)

规格

1mg,5mg,25mg,   50mg, 100mg

克隆号

P84

同种型(Isotype)

Rat IgG1, κ

免疫原(Immunogen)

Mouse brain   membrane protein

成分(Formulation)

PBS, pH   7.0  

Contains no   stabilizers or preservatives

内毒素(Endotoxin)

<2EU/mg (<0.002EU/μg)

Determined   by LAL gel clotting assay

纯度(Purity)

>95%

Determined   by SDS-PAGE

无菌(Sterility)

0.2 μM   filtered

生产(Production)

Purified   from tissue culture supernatant in an animal free facility

纯化(Purification)

Protein A

保存(Storage)

Undiluted at   4°C in the dark

应用(Reported Applications)

In   vivo SIRPα blocking

In   vitro SIRPα blocking

Western blot


Application References:

Yanagita, T., et al. (2017). 'Anti-SIRPalpha antibodies as a potential new tool for cancer immunotherapy.' JCI Insight 2(1): e89140. 

Koskinen, C., et al. (2013). 'Lack of CD47 impairs bone cell differentiation and results in an osteopenic phenotype in vivo due to impaired signal regulatory protein alpha (SIRPalpha) signaling.' J Biol Chem 288(41): 29333-29344. 

Teraoka, Y., et al. (2013). 'Expression of recipient CD47 on rat insulinoma cell xenografts prevents macrophage-mediated rejection through SIRPalpha inhibitory signaling in mice.' PLoS One 8(3): e58359. 

Zen, K., et al. (2013). 'Inflammation-induced proteolytic processing of the SIRPalpha cytoplasmic ITIM in neutrophils propagates a proinflammatory state.' Nat Commun 4: 2436.

Lundberg, P., et al. (2007). 'Osteoclast formation is strongly reduced both in vivo and in vitro in the absence of CD47/SIRPalpha-interaction.' Biochem Biophys Res Commun 352(2): 444-448. 

Oldenborg, P. A., et al. (2001). 'CD47-signal regulatory protein alpha (SIRPalpha) regulates Fcgamma and complement receptor-mediated phagocytosis.' J Exp Med 193(7): 855-862.